Pfizer and BioNTech say late-stage trial shows vaccine effective for 12- to 15-year-olds


Pfizer Inc. PFE, -1.19% and BioNTech SE BNTX, +5.73% said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19. The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile “was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.” BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.

This article was originally published by Read the original article here.

Previous articleEurope Markets: Telecom Italia surges on deal news, as European stocks inch up after weekend of protests over COVID restrictions
Next articleMarket Snapshot: U.S. stocks futures rise as historical bullish pre-Thanksgiving week trading begins


Please enter your comment!
Please enter your name here